A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Inclusion Criteria:

1. Previous completion of a carfilzomib study within 90 days prior to first dose of
maintenance study drug.

2. Disease Assessments performed within 30 days prior to first dose of maintenance study
drug.

3. Written informed consent in accordance with federal, local, and institutional
guidelines

4. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
test, with a sensitivity of at least 50 mIU/mL, within 3 days prior to first dose of
maintenance study drug.

5. Subjects must agree to adhere to the study visit schedule and other study requirements
and receive outpatient treatment and laboratory monitoring at the institution that
administers the drug.

Exclusion Criteria:

1. Administration of an intervening chemotherapy between the time of previous carfilzomib
study termination and first dose of maintenance study drug.

2. Pregnant or lactating females

3. Diagnosis of a new malignancy of a different tumor type.